ReviewCurrent HIV/AIDS reports2025
Role of cccDNA in the Quest for HBV Cure- Implications for HIV-HBV Coinfection.
Review in Current HIV/AIDS reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewHIV co-infection worsens chronic hepatitis B progression, leading to more aggressive disease and higher risk of liver-related death. This review addresses the role of HBV cccDNA, responsible for viral persistence, and the related gaps in knowledge in the perspective of obtaining an HBV cure with special focus on HIV/HBV co-infection. RECENT
findingsHIV/HBV co-infected patients under ART show persistence of transcriptionally active cccDNA. High incidence of HBsAg loss after ART initiation suggests that intrahepatic immune reconstitution might break immune-tolerance to HBV. Open questions remain on the interaction between the two viruses and the liver microenvironment and on the role of emerging serum biomarkers of HBV liver reservoir in co-infected individuals. To clarify HIV/HBV interactions, more advanced models and larger patient cohorts are needed. Insights into cccDNA biology will guide innovative therapies, improving clinical management and access to new HBV cure strategies for co-infected individuals.
Indexed as
Identifiers
41405783What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.